A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
SP2086 is a new dipeptidy1 peptidase(DPP)-4 inhibitors. This study aims to explore the
effective dose range of SP2086 in Patients with type 2 diabetes.